Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery

通过组合设计将硅氧烷掺入脂质纳米颗粒,可增强细胞内加工,从而实现组织特异性mRNA治疗递送。

阅读:8
作者:Lulu Xue # ,Gan Zhao # ,Ningqiang Gong # ,Xuexiang Han ,Sarah J Shepherd ,Xinhong Xiong ,Zebin Xiao ,Rohan Palanki ,Junchao Xu ,Kelsey L Swingle ,Claude C Warzecha ,Rakan El-Mayta ,Vivek Chowdhary ,Il-Chul Yoon ,Jingcheng Xu ,Jiaxi Cui ,Yi Shi ,Mohamad-Gabriel Alameh ,Karin Wang ,Lili Wang ,Darrin J Pochan ,Drew Weissman ,Andrew E Vaughan ,James M Wilson ,Michael J Mitchell

Abstract

Systemic delivery of messenger RNA (mRNA) for tissue-specific targeting using lipid nanoparticles (LNPs) holds great therapeutic potential. Nevertheless, how the structural characteristics of ionizable lipids (lipidoids) impact their capability to target cells and organs remains unclear. Here we engineered a class of siloxane-based ionizable lipids with varying structures and formulated siloxane-incorporated LNPs (SiLNPs) to control in vivo mRNA delivery to the liver, lung and spleen in mice. The siloxane moieties enhance cellular internalization of mRNA-LNPs and improve their endosomal escape capacity, augmenting their mRNA delivery efficacy. Using organ-specific SiLNPs to deliver gene editing machinery, we achieve robust gene knockout in the liver of wild-type mice and in the lungs of both transgenic GFP and Lewis lung carcinoma (LLC) tumour-bearing mice. Moreover, we showed effective recovery from viral infection-induced lung damage by delivering angiogenic factors with lung-targeted Si5-N14 LNPs. We envision that our SiLNPs will aid in the clinical translation of mRNA therapeutics for next-generation tissue-specific protein replacement therapies, regenerative medicine and gene editing.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。